---
figid: PMC5499780__tcrm-13-799Fig1
figlink: /pmc/articles/PMC5499780/figure/f1-tcrm-13-799/
number: F1
caption: 'Mechanisms of action of lenvatinib and everolimus.Notes: Lenvatinib inhibits
  RTKs on endothelial cell and cancer cell. Activated VEGFR and FGFR on endothelial
  cell trigger the MAPK/ERK pathway that promotes angiogenesis. On cancer cell, activated
  RTKs (ie, VEGFR, PDGFR-β, RET, c-KIT, and FGFR) mediate cell proliferation through
  the MAPK/ERK pathway; the activation of PI3K/AKT/mTOR pathway leads to cell survival,
  growth, and motility. Everolimus inhibits mTOR signaling. HIF is degraded by VHL
  in normoxic condition; in the presence of hypoxia, or when overexpressed, it promotes
  angiogenesis through the synthesis of growth factors. Dashed arrows indicate crosslinks
  between different signaling pathways: RAS activates PI3K, whereas mTOR promotes
  HIF expression.Abbreviations: VEGF, vascular endothelial growth factor; PDGF, platelet-derived
  growth factor; TGF-β, transforming growth factor beta; VEGFR, vascular endothelial
  growth factor receptor; PDGFR, platelet-derived growth factor receptor; FGFR, fibroblast
  growth factor receptor; RTK, receptor tyrosine kinase; MAPK, mitogen-activated protein
  kinase; ERK, extracellular signal regulated kinase; PI3K, phosphoinositide 3-kinase;
  mTOR, mammalian target of rapamycin; HIF, hypoxia-inducible factor; VHL, von Hippel–Lindau;
  PDK, pyruvate dehydrogenase kinase; RAS, rat sarcoma; RAF, rapidly accelerated fibrosarcoma;
  MEK, mitogen-activated protein extracellular signal-regulated kinase kinase; ERK,
  extracellular signal-regulated kinase; PIP, phosphatidylinositol phosphate; AKT,
  protein kinase B kinase (AKT8 virus oncogene cellular homolog).'
pmcid: PMC5499780
papertitle: Clinical use of lenvatinib in combination with everolimus for the treatment
  of advanced renal cell carcinoma.
reftext: Alessandro Leonetti, et al. Ther Clin Risk Manag. 2017;13:799-806.
pmc_ranked_result_index: '20890'
pathway_score: 0.9777896
filename: tcrm-13-799Fig1.jpg
figtitle: 'Action of lenvatinib and everolimus.Notes: Lenvatinib inhibits RTKs on
  endothelial cell and cancer cell'
year: '2017'
organisms:
- Mus musculus
- Rattus norvegicus
- AKT8 retrovirus
- Homo sapiens
ndex: ecdd3486-deb8-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5499780__tcrm-13-799Fig1.html
  '@type': Dataset
  description: 'Mechanisms of action of lenvatinib and everolimus.Notes: Lenvatinib
    inhibits RTKs on endothelial cell and cancer cell. Activated VEGFR and FGFR on
    endothelial cell trigger the MAPK/ERK pathway that promotes angiogenesis. On cancer
    cell, activated RTKs (ie, VEGFR, PDGFR-β, RET, c-KIT, and FGFR) mediate cell proliferation
    through the MAPK/ERK pathway; the activation of PI3K/AKT/mTOR pathway leads to
    cell survival, growth, and motility. Everolimus inhibits mTOR signaling. HIF is
    degraded by VHL in normoxic condition; in the presence of hypoxia, or when overexpressed,
    it promotes angiogenesis through the synthesis of growth factors. Dashed arrows
    indicate crosslinks between different signaling pathways: RAS activates PI3K,
    whereas mTOR promotes HIF expression.Abbreviations: VEGF, vascular endothelial
    growth factor; PDGF, platelet-derived growth factor; TGF-β, transforming growth
    factor beta; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived
    growth factor receptor; FGFR, fibroblast growth factor receptor; RTK, receptor
    tyrosine kinase; MAPK, mitogen-activated protein kinase; ERK, extracellular signal
    regulated kinase; PI3K, phosphoinositide 3-kinase; mTOR, mammalian target of rapamycin;
    HIF, hypoxia-inducible factor; VHL, von Hippel–Lindau; PDK, pyruvate dehydrogenase
    kinase; RAS, rat sarcoma; RAF, rapidly accelerated fibrosarcoma; MEK, mitogen-activated
    protein extracellular signal-regulated kinase kinase; ERK, extracellular signal-regulated
    kinase; PIP, phosphatidylinositol phosphate; AKT, protein kinase B kinase (AKT8
    virus oncogene cellular homolog).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VEGFC
  - FLT1
  - FLT4
  - VEGFB
  - EPAS1
  - HIF1A
  - ARNT
  - VHL
  - TGFB2
  - PIK3CG
  - PIK3R3
  - TGFB1
  - PIK3CD
  - FGFRL1
  - PDGFB
  - MTOR
  - KDR
  - PDK1
  - PIK3R6
  - PDGFC
  - PDGFD
  - VEGFA
  - MAPK3
  - FGFR1
  - FGFR3
  - FGFR2
  - FGFR4
  - BRAF
  - HRAS
  - KRAS
  - NRAS
  - HIF3A
  - PIK3R5
  - PIK3R4
  - ARNTL
  - PDGFA
  - ARNT2
  - MAP2K1
  - MAP2K2
  - PIK3CA
  - PIK3CB
  - TGFB3
  - VEGFD
  - ARAF
  - RAF1
  - AKT3
  - AKT1
  - PGF
  - MAPK1
  - AKT2
  - Lenvatinib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT
  entrez: '405'
- word: VHL
  symbol: VHL
  source: hgnc_symbol
  hgnc_symbol: VHL
  entrez: '7428'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB2
  entrez: '7042'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB1
  entrez: '7040'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFRL1
  entrez: '53834'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFB
  entrez: '5155'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: PDK1
  symbol: PDK1
  source: hgnc_symbol
  hgnc_symbol: PDK1
  entrez: '5163'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFC
  entrez: '56034'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFD
  entrez: '80310'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR1
  entrez: '2260'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR3
  entrez: '2261'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR2
  entrez: '2263'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR4
  entrez: '2264'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF3A
  entrez: '64344'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNTL
  entrez: '406'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFA
  entrez: '5154'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT2
  entrez: '9915'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB3
  entrez: '7043'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
chemicals:
- word: Lenvatinib
  source: MESH
  identifier: C531958
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC5499780__F1
redirect_from: /figures/PMC5499780__F1
figtype: Figure
---
